TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Academic and Community Cancer Research United
Academic and Community Cancer Research United
Cancer Insight, LLC
San Antonio Military Medical Center
University of Washington
University of California, Irvine
UNC Lineberger Comprehensive Cancer Center
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Georgetown University
Scripps Health